AnaSpec Introduces Thirty-Six New Catalog Peptides

San Jose, CA, August 28, 2007 --( Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced thirty-six (36) new peptides for drug discovery research.

Protease-Activated Receptor-4; PAR-4 Agonist; amide; human
Amyloid Precursor Protein (APP) (667-676); Swedish mutation
AGA-(C8R) HNG17; Humanin derivative
[Gln9]-beta-Amyloid (1-40)
[D-Ser14]- Humanin (HN)
TAT (47-57)-Lys(TAMRA)
Galanin (1-13)/ Galanin Like Peptide (GALP) (9-21); common
Gastrin derived peptide
STT Gelatinase Inhibitor modification; negative control
CTT; Gelatinase Inhibitor
PB1F (262–70) Influenza Gene Product
Yellow Fever Virus Envelope Protein E1
Dengue 1 Fragment; VGIGNRDFV
Dengue 2 Virus Fragment; IGISNRDFV
Generic Protein Kinase Substrate
Dictyostelium Myosin II Heavy Chain; MH-1 (2020-2035)
Neuropeptide W-23 (NPW23); rat
Dok-5 (130-145)
Pannexin-1 (Panx1); Mimetic Blocking Peptide
Obestatin (11-23); rat; mouse
[Des Ala20; Gln34] Dermaseptin
[Cys(Acm)33]-Endostatin (6-49)
NES p120ctn
NES Topoisomerase II alpha (1054-1066)
NES Nmd3p (491-500)
NES Adenoviral E1A
Transglutaminase Substrate; biotinylated
Piscicolin 126
p1025; Acetyl-Adhesin Peptide (1025-1044); amide
Antimicrobial Anionic Peptide; Surfactant; ovine (DDDDDDD)
Antimicrobial Anionic Peptide; Surfactant-associated AP (GADDDDD); ovine
2837b; Hemoglobin Fragment; Plasmepsin II (PM II) substrate; EDANS/ DABCYL

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.

For more information visit

AnaSpec, Inc.
Ping Yang